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Many studies used non-invasive methods to estimate the
prevalence of significant fibrosis and its risk factors in
patients with HIV infection. We evaluated the ability of
APRI and FIB-4 score to differentiate between the differ-
ent stages of fibrosis (no fibrosis/minimal fibrosis = F0-F1
and F2-F4 fibrosis moderate-severe/cirrhosis), taking as a
reference, in the absence of liver biopsy, the hepatic fibro-
sis stratification by FibroScan.
Group 1 was represented by 39 patients with HIV
infection and group 2 by 71 patients with HIV/HBV
coinfection. AUROC was used to calculate for each
group and for each score the optimal value for identify-
ing significant fibrosis. Then we determined the cut-off
value that identifies significant fibrosis with maximum
specificity. The Kappa score was then calculated for the
concordance between methods.
For HIV/HBV coinfected patients, to identify significant
fibrosis score on tally Kappa classification for fibrosis by
APRI versus FibroScan, Kappa=0.494, 95% CI (0.245,
0.742) on the identification of fibrosis (F0-F1 to F ≥2), for
the FIB-4 Kappa=0.481, 95% CI (0.238, 0.725) for both the
moderate concordance. Regarding the comparison of the
two methods APRI and FIB-4 kappa=0.698, 95% CI (0.485,
0.910), significant concordance.
For patients with HIV to identify significant fibrosis
Kappa score tally on the classification of fibrosis by APRI
versus FibroScan Kappa=0.217, 95% CI (-0.424, 0.858) on
the identification of fibrosis (F0-F1 to F ≥2), for the FIB-4
Kappa=0.164, 95% CI (-0.451, 0.779) for both the correla-
tion is reduced. Regarding the comparison of the two
methods APRI and FIB-4 kappa=0.217, 95% CI (-0.424,
0.858), which confirms the low correlation.
There is sufficient evidence that the tests used: APRI
and FIB-4 have the ability to distinguish for both groups
of patients between the two classes of fibrosis (F0-F1 to
F≥2) meaning between patients with and without liver
disease.
Although for patients with HIV infection a low concor-
dance was noted between non-invasive methods for the
diagnosis of fibrosis, in coinfected patients it was moderate
and these tests could be used as evaluation methods in the
monitoring of liver injury especially when the results of
these tests are concordant.
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